[go: up one dir, main page]

AR011082A1 - Heterociclos de 5 miembros con sustitucion por bifenilsulfonilo, su uso para la preparacion de un medicamento asi como medicamento que los contiene - Google Patents

Heterociclos de 5 miembros con sustitucion por bifenilsulfonilo, su uso para la preparacion de un medicamento asi como medicamento que los contiene

Info

Publication number
AR011082A1
AR011082A1 ARP980100244A ARP980100244A AR011082A1 AR 011082 A1 AR011082 A1 AR 011082A1 AR P980100244 A ARP980100244 A AR P980100244A AR P980100244 A ARP980100244 A AR P980100244A AR 011082 A1 AR011082 A1 AR 011082A1
Authority
AR
Argentina
Prior art keywords
zero
medicinal product
alkyl
atoms
independently
Prior art date
Application number
ARP980100244A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19702045A external-priority patent/DE19702045A1/de
Priority claimed from DE19731328A external-priority patent/DE19731328A1/de
Priority claimed from DE1997141636 external-priority patent/DE19741636A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR011082A1 publication Critical patent/AR011082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Heterocíclicos de 5 miembros con sustitucion por bifenilsulfonilo de la formula (I), en la que los símbolos tienen los siguientes significados: R1es hidrogeno, alquilo con 1, 2, 3, 4, 5, 6, 7 u 8 átomos de C o -Ca-H2a-fenilo, que está sin sustituir o sustituido con 1-3 sustituyentes que se relacionanentre el grupo que consta de F, Cl, Br, I, CF3, metilo, metoxi, hidroxi y NR(8)R(9); R(8) y R(9), independientemente uno de otro son H o alquilo (C1-C4);a es cero, 1 o 2; o R1 es -CbH2b heteroarilo (C1-C9), que está sin sustituir o sustituido segun se describe en la memoria descriptiva; b es cero, 1 o 2; oR1 es -Cd-H2d-cicloalquilo (C3-C7); d es cero, 1 o 2; R2 y R3, independientemente uno de otro, son hidrogeno, F,Cl, Br, I, CF3, -CN, -NO2,CH2OR17, CO-R6 o O-R7; R17, R6 y R7 tienen su significado dado en la memoria descriptivia, significan H o alquilo (C1-C4); o R2 y R3 independientemente unoo de otro, son alquilo con 1, 2, 3, 4, 5, 6, 7 u 8 átomos de C, cicloalquilo con 3, 4, 5, 6 o 7 átomos de C o CgH2g-fenilo, que está sin sustituir osustituido, tienen su significado dado en la memoria descriptiva; g es cero, 1 o 2; o R2 y R3 son, independientemente uno de otro, -ClH2l-heteroarilo (C1-C9),que está sin sustituir o sustituido, tienen su significado dado en la memoria descriptiva; l es cero, 1 o 2; o R2 y R3 son, independientemente uno de otro,SOn-R22; n es cero, 1 o 2; R22 es alquilo con 1, 2, 3, 4, 5, 6, 7 u 8 átomos de C, cicloalquilocon 3, 4, 5, 6 o 7 átomos de C o -CsH2s-fenilo, que estásin sustituir o sustituido, tienen su significado dado en la memoria descriptiva; s es cero, 1 o 2; R4 y R5 independientemente uno de otro,son hidrogeno, alquilo con 1, 2, 3, 4, 5, 6, 7 u 8 átomos de C, F, Cl, Br, I, CF3, -CN, -NO2, SOp-R16, CO-R23 o R-24; p es cero, 1 o 2; R16 es alquilo con
ARP980100244A 1997-01-22 1998-01-20 Heterociclos de 5 miembros con sustitucion por bifenilsulfonilo, su uso para la preparacion de un medicamento asi como medicamento que los contiene AR011082A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19702045A DE19702045A1 (de) 1997-01-22 1997-01-22 Imidazol-Derivae mit Biphenylsulfonylcyanamid-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19731328A DE19731328A1 (de) 1997-07-22 1997-07-22 Imidazol-Derivate mit Biphenylsulfonylcyanamid-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE1997141636 DE19741636A1 (de) 1997-09-22 1997-09-22 Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
AR011082A1 true AR011082A1 (es) 2000-08-02

Family

ID=27217050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100244A AR011082A1 (es) 1997-01-22 1998-01-20 Heterociclos de 5 miembros con sustitucion por bifenilsulfonilo, su uso para la preparacion de un medicamento asi como medicamento que los contiene

Country Status (21)

Country Link
US (2) US6335451B1 (es)
EP (1) EP0855392A3 (es)
JP (1) JPH10204064A (es)
KR (1) KR100529479B1 (es)
CN (1) CN1176911C (es)
AR (1) AR011082A1 (es)
AU (1) AU738676B2 (es)
BR (1) BR9800436A (es)
CA (1) CA2227112A1 (es)
CZ (1) CZ18598A3 (es)
HR (1) HRP980025A2 (es)
HU (1) HUP9800112A3 (es)
ID (1) ID19574A (es)
IL (1) IL123013A (es)
MY (1) MY121708A (es)
NO (1) NO311570B1 (es)
NZ (1) NZ329606A (es)
PL (1) PL191575B1 (es)
SK (1) SK284126B6 (es)
TR (1) TR199800084A3 (es)
TW (1) TW593283B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
HU0900792D0 (en) * 1997-10-17 2010-03-01 Ark Therapeutics Ltd Use of renin-angiotensin inhibitors
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19804251A1 (de) * 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PT1197223E (pt) 1999-04-28 2005-04-29 Takeda Pharmaceutical Preventivos/medicamentos/inibidores da progressao de retinopatia simples ou retinopatia pre-proliferativa
AU2002210925A1 (en) * 2000-10-25 2002-05-06 Takeda Chemical Industries Ltd. Preventives/remedies for portal hypertension
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
DK1395566T3 (da) * 2001-05-31 2008-01-07 Vicore Pharma Ab Tricycliske forbindelser, der er nyttige som angiotensin Il-agonister
HRP20040702A2 (en) * 2002-02-04 2005-04-30 Aventis Pharma Deutschland Gmbh Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ace inhibitors forpreventing heart failure and other age-related dysfunctions of organs, age-related diseases and forprolonging lifespan
US6844361B2 (en) * 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006109056A1 (en) * 2005-04-12 2006-10-19 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235708B2 (en) 2005-04-12 2011-11-10 Vicore Pharma Ab New bicyclic angiotensin II agonists
CN101193886B (zh) * 2005-04-12 2014-08-27 维科尔药物公司 三环的血管紧张素ii激动剂
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2010029576A2 (en) 2008-09-02 2010-03-18 Elder Pharmaceuticals Ltd. Anti inflammatory compounds
CN103992276B (zh) * 2014-06-03 2016-08-24 吉林省药物研究院 4’-{[(2,4,5-三取代苯基)-1h-咪唑-1-基]甲基}联苯-2-甲酸衍生物
JP2017521390A (ja) * 2014-07-17 2017-08-03 ユニバーシティー オブ サウザン カリフォルニア 筋骨格系疾患の治療のための方法、化合物、および組成物
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
JP2026502510A (ja) * 2023-01-09 2026-01-23 ヴィコール ファルマ アーベー 選択的アンジオテンシンｉｉ化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0819110B2 (ja) * 1986-06-04 1996-02-28 富山化学工業株式会社 新規なイミダゾール誘導体もしくはその塩およびそれらを含有する抗炎症剤、解熱鎮痛剤または抗関節炎剤
IL98319A (en) 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
JP3290657B2 (ja) 1991-05-01 2002-06-10 メルク エンド カムパニー インコーポレーテッド アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
TW215434B (es) 1992-03-07 1993-11-01 Hoechst Ag
JPH0625229A (ja) * 1992-03-09 1994-02-01 Japan Tobacco Inc 新規なイミダゾール誘導体
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2711368B1 (fr) 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
PT853477E (pt) * 1995-10-06 2003-01-31 Novartis Ag Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico
JP2000501736A (ja) * 1995-12-12 2000-02-15 メルク エンド カンパニー インコーポレーテッド ロサルタンの新用途
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
KR19980070682A (ko) 1998-10-26
PL324418A1 (en) 1998-08-03
HUP9800112A3 (en) 2001-07-30
MX9800611A (es) 1998-10-31
EP0855392A3 (de) 2000-01-05
CN1176911C (zh) 2004-11-24
NZ329606A (en) 1999-10-28
SK7798A3 (en) 1998-08-05
KR100529479B1 (ko) 2006-10-19
SK284126B6 (sk) 2004-09-08
MY121708A (en) 2006-02-28
HU9800112D0 (en) 1998-03-30
IL123013A0 (en) 1998-09-24
AU5215998A (en) 1998-07-30
HUP9800112A2 (hu) 1998-08-28
IL123013A (en) 2003-02-12
US6486189B2 (en) 2002-11-26
TW593283B (en) 2004-06-21
EP0855392A2 (de) 1998-07-29
CN1188760A (zh) 1998-07-29
US20020045761A1 (en) 2002-04-18
TR199800084A2 (xx) 1998-08-21
CZ18598A3 (cs) 1998-08-12
HRP980025A2 (en) 1998-10-31
CA2227112A1 (en) 1998-07-22
JPH10204064A (ja) 1998-08-04
NO980273D0 (no) 1998-01-21
BR9800436A (pt) 1999-09-08
US6335451B1 (en) 2002-01-01
PL191575B1 (pl) 2006-06-30
NO311570B1 (no) 2001-12-10
ID19574A (id) 1998-07-23
NO980273L (no) 1998-07-23
HK1009814A1 (en) 1999-06-11
AU738676B2 (en) 2001-09-20
TR199800084A3 (tr) 1998-08-21

Similar Documents

Publication Publication Date Title
AR011082A1 (es) Heterociclos de 5 miembros con sustitucion por bifenilsulfonilo, su uso para la preparacion de un medicamento asi como medicamento que los contiene
ATE5258T1 (de) (piperidinylalkyl)chinazolin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
BR0110240A (pt) Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
ES2080919T3 (es) Nuevos derivados de bencimidazol y de azabencimidazol, antagonistas de los receptores al tromboxano, sus procedimientos de preparacion, intermediarios de sintesis, composiciones que los contienen.
ES2057809T5 (es) Composicion tintorea a base de 5,6-dihidroxiindolinas y procedimiento para la tincion de fibras queratinicas.
ES8303360A1 (es) Un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina.
PE106099A1 (es) Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicos
ES449596A1 (es) Procedimiento para la preparacion de nuevos derivados de pi-rimidina.
ES411341A1 (es) Procedimiento para la preparacion de compuestos heteroci- clicos sustituidos por un radical guanidinilideno.
CO5080802A1 (es) Nuevos compuestos heterociclicos inhibidores de la fosfodiesteresa iv y su formulacion y uso como productos farmaceuticos
KR960007566A (ko) 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
FR2394584A1 (fr) Melanges de composes azoiques utilisables comme pigments
CO5251476A1 (es) Procedimiento para la preparacion de compuestos de pirazolo [4,3-d] pirimidin-7-onas-3-piridilsulfonilo e intermedios de los mismos
ES425216A1 (es) Procedimiento para la preparacion de nuevas triazolo - 1,5 - benzodiazepinas sustituidas.
PT99250A (pt) Processo para a preparacao de derivados de piperazina
ES381036A1 (es) Medicamentos analgesicos a base de n-(aroilalkil) n'-(alfa-nols) piperacinas y sus derivados, y procedimiento para su obtencion.
ES436742A1 (es) Procedimiento para la preparacion de aceites cosmeticos protectores frente a la luz.
ES449161A1 (es) Procedimiento para la preparacion de nuevas amidinas.
GB2021136A (en) Protonated amino azobenzene dyestuffs, a process for their manufacture and their use for the colouration of synthetic polymeric materials
DE68906827D1 (de) Phenothiazinderivate, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES389921A1 (es) Procedimiento para la preparacion de nuevas 2 - arilamino - imidazolinas (2) sustituidas.
ES2024332A6 (es) Procedimiento para la obtencion de nuevas sulfonamidas.
DE69301639D1 (de) Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung
ES465221A1 (es) Procedimiento para la preparacion de nuevos derivados de 4- ter-buti-3'-clorodifenilamina con actividad antihistaminica.
ES455841A1 (es) Procedimiento para preparar composiciones insecticidas a ba-se de ditiofo-fatos-(-fonatos) de formamidina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure